TGTX · TG Therapeutics, Inc.

TG Therapeutics reported strong first quarter 2026 results, with total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of $194.8 million, representing approximately 63% quarterly growth over the same period last year. The company raised its full-year 2026 BRIUMVI U.S. net product revenue guidance to $885-900 million (from prior $825-850 million) and total global revenue target to approximately $925 million. Net income for Q1 2026 was $19.8 million, compared to $5.1 million in Q1 2025, driven by higher product revenue. R&D expenses increased slightly to $48.4 million, while SG&A expenses rose to $88.2 million due to increased marketing and commercialization costs. The company also provided Q2 2026 BRIUMVI U.S. net product revenue guidance of approximately $220 million. Management highlighted strong underlying demand, record new patient starts, and consistent commercial execution as drivers of growth. The company secured an additional $500 million in non-dilutive capital from Blue Owl Capital and expanded its share repurchase program to $300 million, with $200 million remaining. Cash, cash equivalents and investment securities stood at $572.8 million as of March 31, 2026. Pipeline milestones include topline Phase 3 data for the ENHANCE trial (consolidated IV dosing) expected mid-2026, and subcutaneous BRIUMVI data by year-end 2026/first quarter 2027.